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Introduction
1. Cancer
Research has aimed to categorize a series of biological capabilities essential for
the long-term viability of a tumor. Simply recognizing the capabilities is not an end in
itself; these hallmark capabilities act as targets for specific therapies with the goal of
reducing the threat of the tumor. One cornerstone paper has claimed there are eight
hallmarks of cancer that enable tumor growth and metastatic dissemination(Hanahan &
Weinberg 2011). These include sustaining proliferative signaling, evading growth
suppressors, activating invasion and metastasis, enabling replicative immortality,
inducing angiogenesis, resisting cell death, deregulating cellular energetics, and
avoiding immune destruction. In this study, I focus on the last emerging hallmark, the
immune destruction of cancer cells in the form of cytotoxic T-cells.
The first of the eight hallmarks is sustaining proliferative signaling (factors that
signal for tumor cell reproduction)(Hanahan & Weinberg 2011). Cell signaling refers to
the mechanisms used by cells to communicate with each other(Solomon, et al. 112-113).
There are several key steps in the process of cell signaling, including the synthesis and
release of signaling molecules, transport (of signaling molecules) to the target cell,
reception of information by the target cell, and the response of the target cell to the
information received(Solomon, et al. 112-113). Tumor expansion can be enabled either
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through the sustained production and release of growth promoting signals (Hanahan &
Weinberg 2011), or through the stimulation of non-cancerous cells to contribute growth
factors(Cheng, et al. 2008; Bhowmick et al. 2004). In addition, the amount of proteins
that act as receptors to the growth factor (on the cell surface) can be increased, leading
to a response similar to that of increasing the growth factor (without any increase in
growth factor levels).
Even with sustained proliferative signaling in effect, the tumor cannot expand
continually unless it can evade several different suppressors and programmed cell
death. One such growth suppressor is the retinoblastoma protein (Rb), which shuts
down the reproductive process if the cell signals to divide while not in the correct
reproductive stage(Burkhart & Sage 2008). Another is the transformation-related
protein 53 (TP53), which signals for a cell to undergo apoptosis (programmed cell
death) if the cell’s DNA is irreversibly damaged, or signals for repair if damage is
minimal(Hanahan & Weinberg 2011). Certain point mutations affect the genes
associated with tumor suppression in these proteins, limiting or eliminating their tumor
suppressing qualities, which allows the tumor to evade programmed cell death and
continue expansion.
Another cancer hallmark is reprogramming the energy metabolism to fuel
increased cell production(Hanahan & Weinberg 2011). Under non-cancerous and
normoxic (normal amounts of oxygen present) conditions, cells convert glucose to
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pyruvate through a process called glycolysis. This pyruvate is then oxidized in the
mitochondria, using oxygen to fuel the process(Hanahan & Weinberg 2011). If there is
not enough oxygen present, however, cells will undergo glycolysis through
fermentation instead of sending pyruvate to the mitochondria (Warburg 1956). This
process can create energy when there is not enough oxygen to create the required
energy through respiration, reducing the metabolic processes’ dependency on oxygen.
Despite using less oxygen in energy production, tumor cells still need a supply of
oxygen and nutrients to survive. While very small tumors in their initial stages can rely
on existing vasculature, after the tumor radius reaches ~200 microns, the peripheral
cancerous cells cannot be reached by the diffusion of oxygen and become hypoxic (the
state of lacking oxygen)(Hanahan & Weinberg 2011). When hypoxia occurs, cancer cells
signal for vasculature expansion to these regions in the form of angiogenesis(Ferrara
2009).
To continue to grow, cancer cells must activate invasion, the spreading of cancer
cells to outside of the basement membrane, and metastasis, the development of
secondary growths at other sites(Hanahan & Weinberg 2011). This process is referred
to as the invasion-metastasis cascade, which begins with intravasation, or the invasion
of cancerous cells into either blood or lymphatic vessels(Talmadge & Fidler, 2010).
Cancer cells then travel through either the blood or lymphatic systems before
undergoing extravasation, when the cancer cells leave the vessel. In the new space they
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form nodules, which under favorable (or rather detrimental to the host) circumstances
can grow into macroscopic growths.
Another hallmark of cancer is enabling replicative immortality, or the ability for
cancer cells to divide indefinitely(Hanahan & Weinberg 2011). To reach macroscopic
sizes, cancer cells need to be able to reproduce but are limited in that each individual
cell can only divide a limited number of times. The limiting factor is the telomeres at
the ends of each chromosome. With each cell division, telomeres shorten until there is
not enough to protect the ends of the chromosomal DNA(Blasco 2005). At this stage,
the cell becomes senescent (no longer able to grow or divide). Cancer stem cells (CSCs)
have a key role in replicative immortality, since they can create progenitors with full
telomeres (Blasco 2005).
Finally, the last hallmark, evading immune system responses, is the focus of this
study(Hanahan & Weinberg 2011). The immune system can send various types of Tcells to the tumor site, with each type fulfilling a unique role. This study looks at such
T-cells, specifically the ‘killer’ (CD8+) variety.
2. Angiogenesis
Angiogenesis is the creation of new blood vessels. When a tumor reaches
roughly 200 microns in diameter, cells become hypoxic due to the lack of oxygen caused
by the limited range of the diffusion of blood. In response, the so coined ‘angiogenic
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switch’ is activated by cancer cells through growth factor signaling, which recruits
blood vessels to supply oxygen to the hypoxic cells (Hanahan & Folkman 1996). This
switch is controlled through a balance of chemical factors that bind to endothelial
receptors, most notably vasculature endothelial growth factor-A (VEGF) and
thrombospondin-1 (TSP-1) (Baeriswyl & Christofori 2009, Bergers & Benjamin 2003).
TSP-1 is known to naturally inhibit angiogenesis, while VEGF signals for angiogenesis
to occur. In most non-cancerous conditions, the angiogenic switch is maintained in its
“off” state by an overabundance of growth suppressing factors (including TSP-1) in
comparison to negligible amounts of growth factors (such as VEGF)(Baeriswyl &
Christofori 2009). In cancerous conditions however, the angiogenic switch is kept in its
“on” position through the presence of various factors, such as VEGF, in order to
provide vital oxygen and nutrients to the expanding tumor. In addition to a hypoxic
environment, genetic mutations may also cause the VEGF gene to be over-expressed,
leading to the release of VEGF from normoxic cells(Ferrara 2009, Gabhann & Popel
2008; Carmeliet 2005).
Interestingly, once angiogenesis occurs in a tumor microenvironment, the rate of
vascular growth proves inconsistent.

Newly formed vasculature often contains

prematurely produced sprouts, abnormally high amounts of branching, enlarged vessels,
microhemorrhaging, and leaks(Baeriswyl & Christofori 2009; Bergers & Benjamin 2003).
A collection of factors in the stromal microenvironment including hypoxic cells, growth
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factors, chemokines, and immune cells, control the amount of VEGF the endothelial cells
are exposed to(Hanahan & Weinberg 2011). Variances within the microenvironment
result in differing rates of vasculature expansion, resulting in a vastly varying vascular
structures(Baeriswyl & Christofori 2009). While non-cancerous vascular networks are
well organized and efficient, tumor-induced angiogenesis form irregular and inefficient
systems (Baluk, et al. 2005; Nagy, et al. 2010).
Angiogenesis commences with a sprout comprised of tip cells, stalk cells, and
phalanx cells, (Norton & Popel 2016) which migrate toward the area with the highest
concentration of VEGF(Vempati, et al. 2014). Stalk cells are directly behind the tip cell
and can proliferate, extending the sprout and increasing the diameter of the capillary
(Norton & Popel 2016). Phalanx cells account for the remaining cells in the chain; once a
stalk cell proliferates, the newly formed cell is a stalk cell and the old stalk becomes a
phalanx. The newly formed vascular segment continues to grow until it anastomoses,
connecting two immature tips, or a tip to a mature capillary, to form a completed vascular
circuit through which blood flows.
3. Cancer Stem Cells
Cancer Stem Cells (CSCs) are perhaps the most important subtype of cancer cells
and have been described as the foundation of the disease (Clarke, et al. 2006). They are
defined functionally by their ability to recapitulate the generation of a continuously
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growing tumor (Clarke, et al. 2006). This cornerstone ability stems from the different
ways CSCs divide - they can undergo either a symmetric or an asymmetric division.
Symmetric divisions result in two daughter cancer stem cells, each of which retain the
key ability of self-renewal (dividing to create more stem cells). Conversely, an
asymmetric division yields one cancer stem cell and one progenitor cell. Stem cells can
divide an essentially “unlimited” amount of times since they are not limited in the same
way progenitors are (Clarke, et al. 2006). Telomeres are short, repeating structures
found at the ends of chromosomes that are responsible for protecting the ends of the
chromosomal DNA from end-to-end fusions(Blasco 2005). Progenitors lose some
telomeres with each division until there is not enough to replicate further without risk
of genetic damage; this puts them into a state of senescence (where the cell can no
longer divide or grow) (Blasco 2005). Telomerase is a specialized DNA polymerase that
adds telomere segments to the ends of telomeric DNA(Blasco 2005). Present in CSCs,
telomerase allows CSCs to reproduce an (essentially) unlimited number of times. This
is the essence of the hallmark “enabling replicative immortality”; if not for the CSC’s
ability to divide without limit, the tumor could not proliferate after each progenitor had
reached their reproductive limit. The CSCs are what create new progenitors with full
telomeres enabling tumor expansion (Clarke, et al. 2006).
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4. Macrophages
Tumor associated macrophages (TAMs) are an essential cell type found within
the tumor stroma that promote tumor growth and lead to a lower overall survival rate
among TNBC patients (Shih, et al. 2006). One key function of TAMs is regulating
angiogenesis (the creation of new blood vessels) by producing and releasing
angiogenetic factors, or by producing proteases that degrade the extracellular matrix
and release angiogenetic factors (Condeelis, et al. 2006). TAMs can also modify the
paths of existing vasculature to form more coherent blood flow; in normal (noncancerous) conditions this ability is used for routing and/or expanding vasculature to
heal wounds(Condeelis, et al. 2006). In addition to directly affecting tumorigenesis,
TAMs promote chronic inflammation, which plays a key role in the infiltration of Tcells to the tumor stroma (Coussens and Werb 2002). They also have been known to
increase the movement speed of tumor cells, increasing the rate of invasion (Condeelis,
et al. 2006).
Macrophage colony-stimulating factor 1 (CSF1) is a cytokine released by breast
cancer cells that is a primary influence on macrophage recruitment (Riabov, et al. 2014).
Another factor that promotes macrophage recruitment is vascular endothelial growth
factor (VEGF), which is the protein that also signals for angiogenesis to occur (Riabov,
et al. 2014). This creates a correlation between areas with a high density of
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macrophages and areas where intense angiogenesis occurs(Condeelis, et al. 2006), since
VEGF is a factor that signals for both macrophage recruitment and angiogenesis.
5. CCR5+ Progenitors
C-C chemokine receptor 5 (CCR5) is a protein that acts as a receptor for
chemokine proteins. Cancer cells secrete interleukin 6 (IL6) which ‘educate’ lymphatic
cells to in turn produce increased amounts of C-C chemokine ligand 5 (CCL5)(Lee
2014). Progenitors then migrate and proliferate at a higher rate due to the information
brought by the CCL5 through the cell’s CCR5 receptors(Lee 2014). These signals are
only received by the progenitor if it has enough CCR5 receptors; A TNBC cell
expressing a high amount of CCR5 receptors is considered CCR5+, while a lack of CCR5
receptors makes the cell CCR5-. In CCR5+ progenitors, the CCL5 signals for increased
migration and proliferation rates of the progenitor, and about 6% of total progenitors
are found to be CCR5+(Norton, et al. 2017).
6. Triple-Negative Breast Cancer
Breast cancer is a particularly common type of cancer, with one in eight women
developing it in their lifespans (“Triple-Negative Breast Cancer: Overview, Treatment,
and More” 2019). It is the most common cancer in women, and leads to the highest
death rate among Hispanic women and second highest among Asian, American Indian,
black, and white women (“Triple-Negative Breast Cancer: Overview, Treatment, and
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More” 2019). Triple-Negative Breast Cancer (TNBC) is a subtype found in roughly one
in six breast cancer patens (Foulkes, et al. 2010). TNBC tumors are defined by a lack of
three critical receptors: estrogen receptor (ER), progesterone receptor (PR), and HER2
(Foulkes, et al. 2010). This lack of receptors renders endocrine (hormone) and
trastuzumab therapies ineffective (Foulkes, et al. 2010). The accepted common choice
for treatment is chemotherapy, but the survival rates for TNBC are lower than that of
non-TNBC breast cancers when treated with neoadjuvant chemotherapy (Foulkes, et al.
2010). Surprisingly, this is despite a higher rate of complete pathological responses
among TNBC patients (Foulkes, et al. 2010).
7. T-Cells
While many believe in the possibility of a ‘magic bullet’ that could eliminate the
threat of cancer, the scientific community has made great strides in systematically
breaking down and understanding the seemingly innumerable mechanisms that are
altered in cancer. One hallmark of cancer is avoiding immune destruction, and one of
such immune responses to cancer is sending cytotoxic T-lymphocytes (CTLs), also
known as killer T-cells, tumor infiltrating lymphocytes (TILs), or CD8+ T-cells, to the
tumor(Hanahan & Weinberg 2011). These CTLs differentiate into their specialized
form, infiltrate the tumor site, and kill cancerous cells through apoptosis. Studies show
a correlation between the amount of CTLs that infiltrate to the tumor site and a better
prognosis in colon and ovarian cancers (Pagès, et al. 2005; Zhang, et al. 2013).
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The T-cells' process begins outside the tumor area with T-cell differentiation, a
transition into a new specialized form through alterations of the genetic code. Under
normal conditions, so called naïve (non-differentiated) T-cells flow through the
lymphatic vessels from lymph node to lymph node, ready to be dispatched wherever
needed. These lymphatic vessels form a system comparable in many aspects to the
circulatory system, transporting immune cells in a clear fluid called lymph. The T-cells'
natural migration is interrupted when a toxic or foreign substance called an antigen is
detected. Antigens are brought to the lymphatic site by dendritic cells so the T-cells can
differentiate into different types, one of which being the CD8+ cytotoxic
variety(Banchereau, et al. 2000). Along with the antigen, cytokines (a protein produced
by cells to impact other cells in different ways) act as differentiation factors, which
influence which kind of specialized T-cell the naïve one will become (Banchereau, et al.
2000). One such cytokines is IL-10, which promotes naïve T-cells to become cytotoxic
effector T-cells(CTLs) (Banchereau, et al. 2000). With the T-cells differentiated into their
specific roles, the next process is relocating them to the site of the antigens.
There are several factors that lead the CTLs to the areas they are needed. One
study found that CD8+ T-cells respond to inflammatory cytokines and similarly move
toward sites of high inflammation (Weninger, et al. 2001). Cytotoxic T-cells are actually
twelve times more efficient at migrating toward inflamed tissue than their memory Tcell counterparts(Weninger, et al. 2001). This is crucial, with tumor-promoting
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inflammation being an enabling characteristic of tumor longevity(Hanahan & Weinberg
2011). It has been long known that the body sends immune cells to neoplastic growths,
causing inflammation to eradicate the lesion(Dvorak 1986). Although it has been found
this acute inflammation actually enhances tumorigenesis and progression(Hanahan &
Weinberg 2011), it also plays the reverse role in directing T-cell invasions to tumor
sites(Weninger, et al. 2001).
Once inside the tumor, CTLs do not stop moving. A study has shown that
although CTLs hone into the problem area, they move randomly within the
tumor(Mrass, Paulus, et al. 2006). The speed at which they move varies quite a bit
however, with sources claiming anywhere from 6 to 25 microns/minute(Kim and Lee
2012; Boissonnas, et al. 2007). In a straight-line race, this would be up to 60 times as fast
as a macrophage. This increased movement speed does not correlate to a large
displacement over time however, as the average displacement for a 24-hour period is
only 21 microns(Kim and Lee 2012).
Having infiltrated the tumor, the T-cells can kill cells that are dysfunctional or
infected in a variety of different ways. CD8+ T-cells specifically utilize the
perforin/granzyme system to induce apoptosis in the target cell(Boissonnas, et al. 2007).
Granzyme is a protease released by granules in the cytoplasm of the CTLs that trigger
apoptosis. Perforin is a protein that acts as a vehicle and is necessary in transferring
granzyme to the target cell. During a process called degranulation, perforin and
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granzyme are released from the CTL and move together before binding with the target
cell’s surface(Boissonnas, et al. 2007). Here perforin takes on a secondary role, assisting
in internalizing the granzyme in the target by forming a channel in the
membrane(Boissonnas, et al. 2007). It is noteworthy that there are five different types of
granzyme found in humans, A, B, H, K, and M, but A and B are the most ubiquitous
and well-studied(Boissonnas, et al. 2007). Both granzyme A and B kill target cells
through DNA alteration, with B ultimately causing DNA fragmentation and A targeting
sections associated with DNA repair(Boissonnas, et al. 2007).
8. Computational Modeling
Considering the high costs and lengthy procedures associated with in vivo and
clinical research, computational modeling offers a cheaper vehicle for scientific research
without the risk of harming live subjects. Computational modeling is one method of
recreating or simulating real systems and interactions. One advantage of modeling is
there is less non-explainable error that occurs in a computer model. Samples cannot be
contaminated (aside from human made bugs in the code), and there is no
approximation in the counting of things like cells. Models are often more time efficient
as well; our model simulates tumor growth over 75 days, but even on nonsupercomputer it takes only ~8 hours to run. The computer also takes away some
randomness, as the same experiment twice (given the same seed) will produce identical
results. A problem with computational modeling, however, is there could be systems in
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vivo that are not understood yet. When a model is created it could give results that do
not account for these unknowns that real trials always do (following the laws of nature).
In constructing a computational model there are numerous ways to simulate an
experiment, but these overall approaches can be categorized into two distinct types:
discrete and continuous. What separates the two are how the variables (including time)
is represented. In a discrete model, the variable is broken up into discrete periods or
sections, where a continuous model flows through units continuously(Hall 1986). The
most common continuous scientific models are rooted in differential equations, since
time is a dimension that is differentiable. These models excel at showing general trends
in the data over a given time period, whereas discrete models are better suited for
applications where time or the subject can be divided into discrete parts.
An Agent-based model is a type of discrete model and is comprised of a number
of individual agents, with time passing in discrete periods. Each agent acts
independently, assessing the current environment and making decisions based on a set
of rules. The focus of an agent-based model is the interactions between agents, which
can highlight key patterns a continuous model cannot represent(Axelrod 1997). They
can also show unexpected behaviors or trends of the population, as each individual
agent makes its own decisions(Bonabeau 2002). Using an ABM requires a different
paradigm of thought as compared to other types of modeling. In the case of the ABM,
researchers need not concern themselves with how the system works over time; instead,
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the focus is on specific small-scale agent to agent interactions. While ODEs model the
macro-interactions, an ABM models the micro-interactions.
As compared to continuous models, ABMs offer several distinct advantages:
capturing emergent phenomena; providing a natural description of the system; and
being very flexible(Bonabeau 2002). an ABM can capture trends created by individual
components but decoupled from the traits of such components. An example of this is
how traffic is caused by individual agents (drivers in their cars), but the location where
traffic is densest can move in the opposite direction the cars are traveling(Bonabeau
2002). This movement of the system is actually opposite from the movement of each
individual agent. While difficult to describe in equations, an ABM can easily show the
occurrence of such phenomena, and how simple actions of agents can snowball into
large-scale trends. ABMs also provide a more natural description of the system when
the agents are ‘behavioral’ entities(Bonabeau 2002). In the case of cancer cells, each cell
acts behaviorally, migrating, proliferating, and taking other actions in relation to the
cells around themselves. An ABM is an efficient way to model such complex behaviors
and interactions, as equations’ complexities increase exponentially with the individual's
complexities(Bonabeau 2002). The ABM is also a very flexible method of modeling.
Everything from numbers of agents to their specific traits and behaviors can be
adjusted. For instance, changing the parameters in the case of a T-cell insertion in vivo
would mean acquiring new lab mice, preparing them with an insertion of tumor cells,
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waiting for the tumor to reach a desired size, and then inserting the desired number of
T-cells. If the number of T-cells were to be changed, this process would have to be
repeated, where the parameter could be changed within seconds in an in silico trial.
This effect compounds if the parameter space is multi-dimensional.
In this project I expand upon an agent-based model of a Triple-Negative Breast
Cancer (TNBC) tumor by including a therapy that targets one key ability of cancer
longevity by injecting cytotoxic T-cells into the system. Within this model I simulate a
CTL therapy, to highlight their effect on tumor progression.
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Methods
1. TNBC Model:
In this project, I continue development of a combined agent-based model of
triple-negative breast cancer and angiogenesis, based on several previous studies
(Norton & Popel 2016, Norton, et al. 2017, Norton, et al. 2018). The model includes a
vascular network, cancerous progenitor cells, cancer stem cells (CSCs), tumor associated
macrophages (TAMs), and CCR5+ cells. I specifically contribute a new module to the
model, adding another type of cell to the environment, the CD8+ cytotoxic T-cell..
2. Initial Setup:
This model operates in a simulated 1-millimeter cubed (1000 micron cubed)
space, which is represented by two separate grids. The cellular grid is of size 50 x 50 x
50 with each voxel representing the space needed to fit one cell, a 20 x 20 x 20 microncubed volume. It initially contains 350 individual cells, 250 of which are stromal TAMs
placed randomly throughout the space. The tumor is comprised of the remaining 100
cells, divided into 80 cancerous progenitors and 20 CSCs. They are initially arranged
into a small box in one corner, and of these tumor cells, 1 stem and 5 progenitor cells are
declared as CCR5+.
A separate grid of size 1000 x 1000 x 1000 contains the vascular network, with
each voxel representing a 2 x 2 x 2 micron cubed space. The initial ‘host vasculature’ is
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comprised of 8 capillaries that run vertically along the edges of the space. Each
capillary is 10 microns in diameter and remain in a fixed position throughout the
simulation. 6 of such capillaries span the entirety of the z axis; 3 lay on the x axis and 3
on the y axis. On each axis (x and y), one capillary is placed toward either side with one
roughly bisecting the axis. The remaining two capillaries are simply branches
stemming from another capillary.
Each capillary in the host vasculature is comprised of 20 linked endothelial cells
which can branch to form new vasculature. All vasculature created during the
simulation can be traced back to an initial capillary. We assume the vasculature grid
can overlap with the cellular grid due to interstitial space and the fact that cells in a
tumor compress, allowing the relatively small vessels to fit in-between cells.
3. Model Iterations
After completing initial setup tasks the model can begin, running for 300
iterations; each iteration is approximately 6 hours in real time. Each iteration begins
with the CD8+ T-cell module (if they are present in the space), followed by macrophage
migration, angiogenesis module, and tumor cell module. Finally, macrophages can
infiltrate, and apoptosis occurs before looping back for another iteration. Each
simulation was conducted on MATLAB R2018a.
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4. Macrophage Migration (Norton et al.)
Macrophages migrate through the tumor space in differing ways; separated from
the tumor, a macrophage migrates with random trajectories at a rate of 3.33 microns an
hour. However, if a cancerous progenitor cell is within a 200 micron range of a
macrophage, the macrophage will migrate toward the closest progenitor with an
increased speed of 26.67 microns per hour. This attraction is due to a factor (CSF-1)
released by cancerous cells. Macrophages will migrate until they reach the edge of the
cellular grid and can only migrate into an empty space.
5. Angiogenesis Module (Norton et al.)
The angiogenesis module of the model is the most involved section, beginning
with the tip cells’ actions. They can migrate and if applicable, proliferate. The stalk
cells act next, proliferating if able. Anastomosis may occur during either the tip or stalk
cells’ turns if a viable target is found. Finally, the branching of a new sprout can occur
under the correct conditions.
a. Tip Cells
Tip cells undergo two main processes each iteration (if applicable): proliferation
and migration. Each tip cell can only proliferate once, and the timing of the
proliferation is determined by a cell clock. Once the tip cell has reached the right period
of its cell cycle (7 iterations or 42 hours) it proliferates, becoming a new stalk cell in the
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same location. A new tip cell is then created in the direction the proliferating tip was
facing, but this new tip cell does not reset the cell cycle and allow for another tip
proliferation. This new tip cell can migrate toward the highest concentration of
vascular endothelial growth factor (VEGF), which is produced in equal amounts by
cancerous cells and macrophages in the model. Each progenitor releases 20 nanograms
per milliliter of VEGF into the space it occupies. During migration, tip cells check the
surrounding 27 spaces in the cell grid and migrate in the direction of the highest VEGF
concentration. Tip cells cannot migrate off the grid or in a direction backwards from
where they were facing. The amount of VEGF in the space also plays a role in
determining the distance the tip cell may migrate, but the tip cell cannot migrate more
than 150% of its current length or more than 60 microns. Once migration is completed,
the tip checks for a possible target to anastomose with.
b. Stalk Cells
Tip cells are limited to a single proliferation, thus, stalk cell proliferation allows
the vasculature to continue growing (stalk cells also do not migrate). Stalk cell
proliferation is also based on a cell clock; when the stalk cell is in the right phase of its
cell cycle (6 iterations or 36 hours), it proliferates. A new stalk cell is created in the
direction the previous one was headed. Its cell clock is reset allowing for multiple
rounds of proliferation. The original stalk cell becomes a phalanx cell which no longer
proliferates or migrates. Similarly to tip cells, the stalk cells cannot proliferate if the tip
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cell will be forced outside the cellular grid. After a successful proliferation, the tip cell
checks for a possible anastomosis target.
c. Anastomosis
When a tip cell migrates and is pushed within range of either another tip cell or
other endothelial cell anastomosis can occur, fusing the two sections of vasculature
together to make one mature capillary. Once anastomosis occurs, tip cells of both
joining halves become deactivated and the cells that comprise the new capillary can no
longer proliferate or migrate. Mature vasculature has blood flowing through it,
bringing nearby cells out of a hypoxic state.
d. Sprouting/Branching
Branching, or the creation of a new sprout, occurs only within the cells
comprising mature blood vessels. If the segment is within 250 microns of a hypoxic cell,
there is a 20% chance for sprouting to occur each iteration. If triggered, the new sprout
will form out of the existing blood vessel, facing toward the nearest hypoxic progenitor.
This new sprout is a tip cell, and once it branches from the capillary the two
surrounding cells can no longer branch.
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6. Tumor Cell Module (Norton et al.)
The tumor cell module encompasses several different cell types, and several
different processes for each cells to complete. The tumor is comprised of both
progenitors (CCR5- and CCR5+), and CSCs, which both migrate and proliferate.
Progenitor cells can become hypoxic (in a state of lacking oxygen) under correct
conditions, while CSCs are considered immune.
a. Progenitors
While the simulation begins with only 80 progenitor cells, they very quickly
become the most ubiquitously found cell in the simulation. This is mainly because of
their relatively quick rate of proliferation, which occurs once every 2 days. Being within
a 200 micron range of a macrophage further increases progenitor proliferation rate by
3.5-fold. The limiting factor of progenitors is not the rate at which they can reproduce,
it is the number of divisions they can undergo. Each progenitor has only enough
telomeres for 12 divisions before it can no longer reproduce, and upon division this
number is not reset for its child. For instance, if a new progenitor divides, both children
progenitors will have 11 divisions remaining each. During proliferation, each new cell
has a 6% chance to be CCR5+. Progenitors migrate relatively slowly (at .83 microns per
hour) and migrate randomly. If migration occurs, the progenitor will check the
surrounding 26 cell spaces and randomly choose an empty one to migrate into. While
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the migration of progenitors is relatively slow, there are several factors that increase
their migration rate. If the progenitor is within a 200 micron range of a macrophage it
will migrate at 2.5 times as quickly, and if it is CCR5+ it will migrate 10 times as fast as a
CCR5- progenitor.
b. Hypoxia
Progenitor cells are affected by hypoxia and will enter a hypoxic state if further
than 200 microns from the nearest active blood vessel. Hypoxic progenitor cells migrate
at 3 times the normal rate but proliferate at half the normal rate. At the end of each
iteration, 10% of hypoxic cells are killed off by apoptosis. CSCs, TAMs, and CTLs are
unaffected by hypoxia in this model.
c. CSCs
Cancer stem cells share many properties with their progenitor counterparts,
including migration and proliferation; they differ in several key areas, however. A
majority of CSC division is asymmetric, resulting in one CSC and one progenitor cell.
Newly created progenitors begin with the maximum amount of possible divisions. CSC
symmetric division occurs roughly once every 5 days, producing 2 daughter CSCs, and
stem cell proliferation is not limited by telomeres. Stem cells are also not killed by
hypoxia in this simulation, and the only way they can die is through a CD8+ T-cell
killing it off directly.
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7. Macrophage Infiltration (Norton et al.)
Macrophages enter the simulation through mature vasculature, and are attracted
to factors secreted by tumor cells. If there is a cancer cell within a 200 micron range of a
mature blood vessel, there is a 60% chance a macrophage is recruited into the space.
First, we check to ensure at least one of the 27 spaces in the cellular grid around the
endothelial cell is empty, then the macrophage will choose one randomly to infiltrate
into.
8. Apoptosis
At the end of each iteration apoptosis occurs if there are hypoxic or senescent
cells. 10% of the total hypoxic and 10% of senescent cells are eliminated.
9. T-cell Module (Ventoso)
This version of the TNBC model is differentiated from previous editions by the
introduction of the T-cell module. Initially the model is devoid of any T-cells, allowing
the tumor to proliferate. After a predetermined 200 iterations (50 days), a certain
number of TILs (either 10 or 25) are inserted into the simulation. The TILs are inserted
randomly into the tumor space, and act at the beginning of every iteration. During each
iteration we loop through every individual T-cell in a random order and depending on
several factors, each can undergo four main processes: migration; killing of nearby
cancerous cells; proliferation; and undergoing apoptosis.
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Each T-cell migrates through the space randomly. The average total
displacement for a T-cell is ~20 microns per day, so each iteration we give each T-cell a
25% chance of migrating one 20-micron space away each 6-hour iteration. If the
migration occurs, the cell will check all of the surrounding spaces in the agent matrix
and store a list of all which are empty. It then randomly chooses one space from the list
of empty spaces to migrate into.
Next, each CTL on average kills one cancer cell per day. In the model, each CTL
has a 25% chance every 6-hour iteration to kill a nearby cancerous cell. After checking
whether it will kill, the T-cell must check for applicable targets. A function returns a list
of any progenitor or cancer stem cell adjacent to the CTL, and if the list is not empty, a
random cell is chosen from the list. That cell is then killed through apoptosis.
CTLs can also proliferate at an average rate of one division per 8 hours. Since
this equates to an average of three divisions a day, for each 6-hour iteration we give
each T-cell a 75% chance of proliferation. If the T-cell will proliferate this iteration, it
first checks the surrounding spaces for an empty cell. If an empty space is available, a
random point is chosen out of all possible empty spaces, and a new CTL is inserted into
the simulation at the chosen coordinates. Care is taken to ensure the newly formed CTL
does not take any actions, nor does its cell clock start counting, until the following
iteration. Considering the relatively low death rate, CTLs would quickly overwhelm
the model if not for a limit on proliferation. The period of proliferation for T-cells is
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only 4 days. After those 16 iterations no more T-cell proliferation can occur, and the
remaining T-cells simply finish out their existences. This in turn, leads to a very rapid
(exponential) growth of CTLs with a more moderate descending taper.
Finally, T-cells have a lifespan of ~2 days, which is represented in the model as 8
six-hour iterations. A timer keeps track of how much time each T-cell has left, with new
CTLs starting at 8 and counting down to 0. If a CTL’s cell clock reaches 0, it is marked
for apoptosis and killed at the end of the T-cell module.
10. Statistical Analysis
First, to ensure all data is normally distributed, I did several Shapiro-Wilk normality
tests as shown in Table 2 at the end of the Results. With an alpha of .05 each test
suggested normality among the data sets, therefore allowing all other tests to assume
normality (data is suggested to be normal when W is greater than the critical value).
To compare how the treatments affected the tumor size (measured in number of
cancer cells) at the end of each trial, I performed a one-way ANOVA. Finding
significant differences, I performed a Tukey Honestly Significant Difference test as post
hoc. In calculating differences between the two treatments, I used a onetailed independent sample Student’s T-tests. For looking at how effective the (random)
killing of a CSC is, I performed several Pearson correlations tests. In these tests, the two
populations being compared span across the parameter space, as the number of T-cells
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is not strictly dictated by the number of CTLs. In plotting the correlation data, I
also performed linear regressions.
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Results
I developed a T-cell module for an agent-based model of triple-negative breast
cancer. To show the effects of increasing the number of T-cells in the tumor, I ran
simulations varying the number of T-cells inserted. For one simulation, 10 CTLs were
inserted at iteration 200 (the 50th day). In the next, 25 CTLs were inserted at iteration
200. Finally, a control simulation was conducted with no CTL insertion. Each
simulation consisted of 6 trials with random seeds.

Figure 1. The top row depicts an example of vascular growth over time, while the bottom row shows the tumor’s
growth over the same time frame. Blue cells are progenitors, while red cells are CSCs. The first column is
iteration 10 (2.5 days), the second is iteration 80 (20 days), and the third column is iteration 150 (37.5 days).
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In Figure 1 I show examples of both major aspects of the simulated tumor, the
vascular and cell grids, at certain intervals to show the tumor’s progression. The top
row of figures depicts the vascular network, while the bottom row contains the
corresponding tumor state, with progenitors in blue, cancer stem cells in red. Until the
50th day, the tumor can proliferate freely with hypoxia being the only factor responsible
for the death of cells. Figure 2 shows the effects of the CTLs of the model by depicting
an example trial (with 10 initial CTLs) before, during, and after the CTL stage.
A. Increasing initial amounts of CTLs in the tumor space decreases overall tumor
size
It has been hypothesized that an invasion of CTLs into the tumor space can
reduce tumor size over a relatively short period of time but do not effectively eradicate
the entire tumor (leading to the importance of memory T-cells)(Maimela 2018). I
performed a one-way independent ANOVA, comparing the number of cells comprising
the tumor after the end of 300 iterations (75 days). It shows that there are significant
differences among the treatments F(2,15) = 7.1067 , p < .05, np2 = .47 (large), MSE =
316,725,565.5 with a large effect size. To follow this up, I performed a Tukey honest
significance test with A being no CTL insertion, B being 10 initial CTLs, and C being 25
initial CTLs. With a HSD value of 6884.7, there is significance between A and B with a
mean difference of 7444.5 and between A and C with a mean difference of 9507.0,
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shown in Table 1. There was no significant difference between B and C however, with a
mean difference of only 2062.5.

Figure 2. Displayed are the means with a 95% confidence interval for the size of the tumor over time (measured
in number of cancer cells). During trials with a T-cell insertion, there is a clear decrease in tumor size during the
period the CTLs act (iteration 200-224).
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Table 1:
Treatment
A: Control
B: 10 initial CTLs
C: 25 initial CTLs

Mean (Standard Deviation)
# of Cells at Iteration 300 (75 days)
20,057.0 (4,082.5)
12,612.5 (4,852.7)
10,550 (4,809.3)

B. Increasing amounts of CTLs increases the number of cancerous cells killed
While the number of CTLs in the space at the peak is more than double when
starting with 25 instead of 10, the number of cells killed off is nowhere close to double.
A one-tailed independent T-test was performed analyzing the total number of cells
killed by CTLs during their time in the simulation. This T-test showed that the total
amount of kills when inserting 10 CTLs into the tumor space (Mean = 5136.7, SD = 761.3)
is significantly lower than inserting 25 CTLs into the space (Mean = 6421.5, SD = 1186.9),
t(10) = 2.04, p < .05. While there is statistical significance, the difference in means shows
that having a tumor environment super-saturated with killer T-cells does not kill a
proportionate (to number of T-cells present) number of cells. More than an average
30,000 CTLs at peak lead to an average mean difference of only 1284.83 more kills on
average over the 6 days; this is a mere 25% return on having more than 150% additional
CTLS.
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Figures 4/5. Depicted (left) is the mean number of CTLs in the tumor at a given time, with a 95% confidence
interval. On the right we show mean the number of cancer cells killed by the CTLs each iteration and a 95%
confidence interval for the given parameters. Note the drastic difference in the number of CTLs versus how
many cancer cells they are able to destroy.

C. A higher number of CSCs killed strongly correlates with a smaller tumor size

over time and a decreased tumor proliferation rate
One interesting result is that since the number of CSCs in the space greatly
affects overall tumor proliferation and size over time, higher amounts of CSCs killed by
CTLs will lead to overall lower tumor size. To investigate, I used a Pearson Correlation
test to compare the number of CSCs in the space at iteration 225 (directly after all killing
is completed and no more CTLs are present) and the overall size of the tumor in
number of cells at iteration 300. This test utilizes data from all trials across the
parameter space, since we are not looking at CTLs directly. The Pearson Correlation
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Test shows a strong positive correlation between number of CSCs present at iteration
225 and total size of the tumor at iteration 300 with R(16) = .8821, a critical value of .590
for alpha < .01, and an effect size R^2 of .7781. Figure 5 shows a plot of the data
analyzed with a line of best fit clearly showing the positive correlation.

Figure 5. Pearson Correlation between the number of CSCs after the T-cell therapy completes and the size of the
tumor at day 75, with a linear regression line.
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To further investigate, I did another Pearson Correlation Test between the
number of CSCs present at iteration 225 and the net tumor growth between iteration
225 and 300, counted in number of cells at 300 minus number of cells at 225. This time it
showed a small but positive correlation of R(16) = .3275.

Figure 6. Pearson Correlation between the number of CSCs after the T-cell therapy completes and the net change in cells
from directly following the T-cell therapy to the end (iteration 300 minus iteration 225), with a linear regression line.
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This does not consider the number of cells that end up dying due to hypoxia
however, so I ran one more Pearson Correlation Test between number of CSCs at
iteration 225, and the total number of cell proliferations occurring between iteration 225
and 300. This time however, the test showed a very strong positive correlation with
R(16) = .9459.

Figure 7. Pearson Correlation between the number of CSCs after the T-cell therapy completes and the total number of
tumor proliferations between when the T-cell therapy ends and the end of the simulation (iteration 225-300), with a
linear regression line.
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Table 2: Shapiro Wilk Tests
Data

n

Critical Value (α=.05)

W

ANOVA Group A
ANOVA Group B
ANOVA Group C
T-Test- 10 CTLs
T-Test 25 CTLs
Pearson- # of CSCs at day 56
Pearson- Size of Tumor
Pearson- Net Growth
Pearson- Total Tumor Proliferations

6
6
6
6
6
18
18
18
18

.788
.788
.788
.788
.788
.897
.897
.897
.897

.878
.895
.903
.895
.919
.934
.937
.922
.958
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Discussion
The data shown in terms of T-cell actions matches in vivo studies’ findings. As
shown by Figure 2, there is exponential growth followed by a tapered decay, which
follows the know Gomperzian tumor growth curve (Kim 2012; Laird 1964). When
starting with 10 CTLs there are ~24,000 CTLs present at the peak, which is a density of
about 1536 CTLs per 400 microns cubed, and thus 77 CTLs per 400 microns squared.
This is very similar to in vivo studies, which show an average of 81 CTLs in 400 microns
squared of tumor stromal tissue (Shimizu, et al. 2019). The ~50,000 CTLs that result
from 25 initial CTLs is only marginally more than the average ~33,400 that have been
found naturally in tissue at the periphery of the tumor(Shimizu, et al. 2019). These
CTLs are inserted into the space and allowed to act with the goal of diminishing the size
of the tumor as much as possible. They kill, move, and stay in the simulation
comparably to other studies(Kim 2012; Yee 2002). While T-cell insertions in very large
amounts (~1x10^7) are becoming more popular for in vivo studies, it is difficult to
specifically analyze the effects of only the CD8+ class of T-cells. While a large majority
of the T-cells injected in such studies are CD8+, there are still the other three types in the
mix. Additionally, T-cells can differentiate, leading to multiple subtypes with each
taking on different roles, which is very difficult to control in vivo.
While there was statistical significance in terms of how many total cells the CTLs
were able to destroy, the difference (in means) between the two parameters is not very
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important in terms of validating a treatment method. In looking at the amount of Tcells in the space versus how effective they are at reducing the size of the tumor, it is
apparent that even a super-saturation of CD8+ killer T-cells in the tumor environment is
not enough to kill off the tumor completely. If an overestimated amount of CTLs in the
tumor space cannot kill off the tumor, perhaps such killer T-cells are not a viable
standalone treatment. This could likely be equated to either their rather short window
of proliferation, or how they do not linger for very long after the proliferation window
closes. Either way, having only a 6 days opportunity to eliminate the tumor is simply
not enough time for the CTLs to eradicate the threat, although it is on par with what
other studies show.
One interesting result from this study is in the relation of CSCs to the tumor’s
ability to recover from the CTL stage. Lower levels of CSCs present directly following
the CTL stage lead to decreased proliferation and ultimately a smaller tumor size at the
end of the simulation. This directly matches previous research (Norton, et al. 2017) and
our BSRI research results (paper in progress), but at a slightly different angle; instead of
seeking to throttle CSC symmetric division to fight their properties of enabling
replicative immortality, I note it is worth attempting to directly target CSCs with a
therapy to prevent or inhibit the cancer from recovering. Perhaps there is a method to
make CSCs a higher priority target through increased production or overexpression of a
factor, which would significantly increase the effectiveness of the CD8+ T-cells.
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There are several limitations and opportunities for continued study that could be
taken. One limiting factor is with respect to hardware; with trials taking quite a while
to finish (~18 hours each), faster computers or a cluster could have allowed for more
trials to be run. This in turn could mean either more trials over the same parameter
space to increase the accuracy of statistical analysis, or a wider parameter space to
analyze (or both). Another factor that limits this study is that the space is considered
constant, and the cell densities are fixed. Since the cell grid is a matrix and each voxel
can hold one cell, the tumor cannot fill a given space with more cells than there are
voxels. This opposes findings that show tumors often have higher cell densities, with
many cells packed into a smaller volume than normal. This in turn, also affects how
cells become hypoxic, since higher densities mean the same number of cells can fit
within a smaller space closer to vasculature. Furthermore, every cell is assumed to be
the same size with a diameter of 20 microns. While accurate for macrophages, T-cells
have been found to be only roughly 10 microns in diameter. This means that where one
macrophage can fit, 4 T-cells could fit. When dealing with such a large amount of Tcells that ratio becomes very important, as 50,000 T-cells would actually only take up
the space of 12,500 macrophages. Finally, I only do one T-cell insertion, while many in
vivo studies do multiple insertions over time(Shimizu, et al. 2019; Yee, et al. 2002). This
is because some T-cells differentiate into memory T-cells, which increase the
effectiveness of later insertions.
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This study leaves several paths for continued study available. One such are to be
explored in the model is the interactions between the T-cells and the Tumor Associated
Macrophages. It has been known they can act together to create several interesting
effects in combination, and since the model now accounts for both separately, it would
make sense to explore the direct effects of their interactions. This may also lead to
changing the method in which the T-cells enter the space; to control the number of Tcells, a specified (perhaps changing to analyze effects) may be inserted at the beginning
of the trial with proliferation turned off to maximize the amount of control over the
parameter space. On the other hand, to take a more realistic approach one might
simulate the T-cells' invasion through the lymphatic vessels into the tumor region.
There could be set lymphatic vessels in the model with which the T-cells infiltrate
through instead of simply being inserted into the space; this leads to the infiltration rate
being a parameter worth investigating. Another direction possible would be to
incorporate the other types of T-cells into the model. Helper T-cells, Natural-Killer Tcells, and Memory T-cells all play separate but related roles in the body, and although a
large amount of the T-cells that invade the tumor space in vivo are CD8+, the rest of the
types are worth including for their unique effects. Another parameter that might be
worth instigating is the point at which the T-cell invasion begins or when the injection
of T-cells is administered. As I have shown, even an unrealistically high volume of
CTLs in the tumor environment is not enough to kill a tumor after it has had months to
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progress. It may be worth testing the effects of the CTLs on a smaller tumor to at what
point the CTLs are able to overwhelm the tumor and eliminate it completely.
In conclusion, I expanded upon an agent-based model of triple-negative breast
cancer, adding a cytotoxic T-cell module and conducting trials to analyze the CTLs
effect on a growing tumor. I was able to simulate a realistic amount of CTLs, length of
effect, and rate of killing, and my results match other studies, suggesting a killer T-cell
invasion alone is not sufficient in eradicating a tumor.
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